GlassScriptPhysician profile
Steven J Verkaik
NPI 1003804642
$8,999.49
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $853 · 2021: $1,715 · 2022: $1,908 · 2023: $1,888 · 2024: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,203.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,354.18 | 2019-2024 | Wegovy, Saxenda, Ozempic |
| Abbvie INC. | $1,180.75 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $937.13 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $831.69 | 2019-2024 | |
| Lilly USA, LLC | $793.14 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.62 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $386.49 | 2019-2023 | Trintellix, Glassia |
| Amgen INC. | $367.96 | 2019-2024 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $345.30 | 2019-2024 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $265.15 | 2019-2024 | Austedo Xr, Airduo Digihaler |
| Glaxosmithkline, LLC. | $187.57 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $167.48 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $148.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $119.64 | 2019-2023 | Eliquis, Camzyos |
| Exact Sciences Corporation | $119.33 | 2023-2024 | Cologuard Collection Kit |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $112.86 | 2023-2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $108.28 | 2021-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $93.75 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $81.52 | 2019-2022 | |
| Dexcom, INC. | $78.89 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $75.03 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $74.39 | 2019-2023 | |
| Allergan, INC. | $70.42 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $61.16 | 2021 | |
| Currax Pharmaceuticals LLC | $57.19 | 2021-2023 | Contrave, Onzetra Xsail |
| Philips North America LLC | $45.55 | 2021-2022 | |
| Biogen, INC. | $43.17 | 2021 | |
| Sumitomo Pharma America, INC. | $37.09 | 2024 | Gemtesa |
| Genentech USA, INC. | $36.81 | 2019-2020 | |
| Esperion Therapeutics, INC. | $28.47 | 2023-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $26.05 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $24.19 | 2023 | Auvelity |
| Lundbeck LLC | $23.30 | 2024 | Rexulti |
| Seqirus USA INC | $22.46 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Neurocrine Biosciences, INC. | $21.82 | 2024 | Ingrezza |
| Eisai INC. | $20.85 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $19.87 | 2024 | |
| Paratek Pharmaceuticals, INC. | $18.42 | 2022 | |
| Cranial Technologies, INC | $16.64 | 2022 | |
| Hologic Sales and Service, LLC | $16.22 | 2024 | Aptima |
| Boston Scientific Corporation | $14.34 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.84 | 2024 | Voquezna |
| Radius Health, INC. | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Verkaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.